Literature DB >> 15519485

Treatment of brucella spondylitis: lessons from an impossible meta-analysis and initial report of efficacy of a fluoroquinolone-containing regimen.

Georgios Pappas1, Savvas Seitaridis, Nikolaos Akritidis, Epaminondas Tsianos.   

Abstract

Although spondylitis is the most common of the complications of brucellosis, and is often debilitating and difficult to treat, there is no consensus on the preferred combination of antibiotics used. We attempted to perform a meta-analysis based on series on brucellar spondylitis published in the last 22 years. Meta-analysis was aborted largely due to insufficient data recorded in most series. However, useful conclusions could be drawn, such as the importance of prolonged treatment, usually more than 12 weeks. No antibiotic combination was proven to be superior, but 14 different regimens were used in the series studied. The authors propose the use of a combination of doxycycline and ciprofloxacin for a period of 3 months, and report the successful use of such a combination in five patients with brucellosis and spondylitis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15519485     DOI: 10.1016/j.ijantimicag.2004.05.003

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  13 in total

Review 1.  Quinolones for treatment of human brucellosis: critical review of the evidence from microbiological and clinical studies.

Authors:  Matthew E Falagas; Ioannis A Bliziotis
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

2.  Treatment of brucellosis: a systematic review of studies in recent twenty years.

Authors:  Seyed Mohammad Alavi; Leila Alavi
Journal:  Caspian J Intern Med       Date:  2013

3.  Spinal epidural abscess in brucellosis.

Authors:  Ahmet Boyaci; Nurefsan Boyaci; Ahmet Tutoglu; Dilek Sen Dokumaci
Journal:  BMJ Case Rep       Date:  2013-09-26

4.  Clinical characteristics of human brucellosis in patients with various monoarticular involvements.

Authors:  Mile Bosilkovski; Marjan Zezoski; Dijana Siskova; Silvana Miskova; Vesna Kotevska; Nikola Labacevski
Journal:  Clin Rheumatol       Date:  2016-02-09       Impact factor: 2.980

Review 5.  The current therapeutical strategies in human brucellosis.

Authors:  Mile Bosilkovski; Fariba Keramat; Jurica Arapović
Journal:  Infection       Date:  2021-03-01       Impact factor: 3.553

Review 6.  Brucellosis: the case for live, attenuated vaccines.

Authors:  Thomas A Ficht; Melissa M Kahl-McDonagh; Angela M Arenas-Gamboa; Allison C Rice-Ficht
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

7.  Complicated brucellar spondylodiscitis: experience from an endemic area.

Authors:  Aysegul Ulu-Kilic; Merve Sefa Sayar; Ediz Tütüncü; Figen Sezen; Irfan Sencan
Journal:  Rheumatol Int       Date:  2012-11-04       Impact factor: 2.631

8.  Doxycycline plus streptomycin versus ciprofloxacin plus rifampicin in spinal brucellosis [ISRCTN31053647].

Authors:  Emine Alp; Rahmi Kemal Koc; Ahmet Candan Durak; Orhan Yildiz; Bilgehan Aygen; Bulent Sumerkan; Mehmet Doganay
Journal:  BMC Infect Dis       Date:  2006-04-11       Impact factor: 3.090

9.  Brucella melitensis prosthetic joint infection.

Authors:  Domenica Flury; Henrik Behrend; Parham Sendi; Matthias von Kietzell; Carol Strahm
Journal:  J Bone Jt Infect       Date:  2017-04-05

10.  Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations.

Authors:  Javier Ariza; Mile Bosilkovski; Antonio Cascio; Juan D Colmenero; Michael J Corbel; Matthew E Falagas; Ziad A Memish; Mohammad Reza Hasanjani Roushan; Ethan Rubinstein; Nikolaos V Sipsas; Javier Solera; Edward J Young; Georgios Pappas
Journal:  PLoS Med       Date:  2007-12       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.